Facebook
Twitter
LinkedIn
ForwardStem Cell Transplant and Cell Therapies Symposium: Navigating the “New Normal"
PLEASE NOTE: THIS IS A VIRTUAL EVENT VIA ACCELEVENTS
Join clinical leaders from Dana-Farber Cancer Institute and Brigham and Women’s Hospital in the Transplant & Cell Therapies Annual Symposium: Navigating the “New Normal".
Target Audience
This activity is intended for physicians, nurses, social workers, and payors who care for patients with cancer who may be appropriate for cellular therapy treatment. It will feature presentations and panel discussions about the rapidly emerging and evolving cellular therapies, with insight on eligibility, referral guidelines, and post-treatment management.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Demonstrate comprehension of the referral process and care coordination between the community oncologist and the transplant team, including the pre-transplant workup process.
- Identify common and uncommon post-treatment toxicities post-treatment and differentiate between various common, chronic, and advanced infections post-treatment.
- Demonstrate comprehension of the use of haploidentical transplantation and its practicality.
- Review other non-infectious concerns that may present during short-term and long-term recovery from treatment.
- Categorize common toxicities during CAR T-cell treatment 6. Discuss latest therapies in research and clinical practice.
Additional Information
| 9:30am | Welcome & Introduction | Amy Emmert & Kidest Mequanent |
| 9:40 | BREAK |
| 9:45 | Referral Process for Transplant and Immune Effector Cell Therapies and How We Coordinate Care with Referring Clinicians | Corey Cutler, MD & Caron Jacobson, MD |
| 10:25 | BREAK |
| 10:35 | Infectious Disease Management for Transplant and Cell Therapies | Sarah Hammond, MD |
| 11:05 | BREAK |
| 11:15 | Supporting Patients On Their Journey to Stem Cell Transplant | Cindy Albert; Pamela Kostaras; Caroline Johnson |
| 12:00pm | LUNCH/NETWORKING Pre-Recorded Sessions:
|
| 12:45 | The Research Nursing Perspective: The Challenges and Opportunities of Managing Cell Therapies clinical Trial Patients | Elizabeth Kendricken, BSN, RN, OCN |
| 1:15 | BREAK |
| 1:25 | Panel Discussion: Optimizing Stem Cell Transplantation and Cellular Therapies to Meet Demand & Update on the 80/20 Project, Shared Care, and a Network Payor Perspective |
| 2:00 | Closing Remarks | Julie Porter |
| 2:05pm | Adjourn |
Course Director
Corey Cutler, MD, MPH, FRCPC
Medical Director, Division of Transplant and Cell Therapies,
Dana-Farber Cancer Institute
Faculty
Cindy Albert
Director, Donor & Business Services,
Stem Cell Transplant and Cell Therapies,
Dana-Farber Cancer Institute
Anthony Bonagura, MD
Senior Medical Director, Optum
Amy Emmert
Executive Director, External Affairs HSCT & Cellular Therapy Service Line,
Dana-Farber Cancer Institute
Sarah Hammond, MD
Assistant Professor of Medicine, Harvard Medical School;
Director, Hematology/Oncology Infectious Disease,
Massachusetts General Hospital
Vincent Ho, MD
Director, Clinical Operations, Stem Cell Transplantation,
Dana-Farber Cancer Institute
Caron Jacobson, MD
Assistant Professor of Medicine, Harvard Medical School;
Lymphoma Clinical Investigator,
Director, Immune Effector Cell Therapy Program,
Dana-Farber Cancer Institute
Caroline Johnson
Resource Specialist,
Stem Cell Transplant and Cell Therapies,
Dana-Farber Cancer Institute
Amy Joyce, NP
Nurse Practitioner,
Stem Cell Transplant and Cell Therapies,
Dana-Farber Cancer Institute
Elizabeth Kendricken, BSN, RN, OCN
Clinical Research Nurse,
Stem Cell Transplant and Cell Therapies,
Dana-Farber Cancer Institute
Pamela Kostaras
Manager, Cell Therapies Coordination,
Stem Cell Transplant and Cell Therapies,
Dana-Farber Cancer Institute
Kidest Mequanent
Senior Program Manager, Cell Therapies and Shared Care,
Dana-Farber Cancer Institute
Clifton Mo, MD
Director, Autologous Stem Cell Transplantation for Multiple Myeloma,
Dana-Farber Cancer Institute
Omar Nadeem, MD
Clinical Director, Myeloma Immune Effector Cell Therapy Program,
Dana-Farber Cancer Institute
Sarah Nikiforow, MD, PhD
Assistant Professor, Harvard Medical School;
Stem Cell Transplant Program,
Medical Director, Cell Manipulation Core Facility (CMCF),
Technical Director, Immune Effector Cell Therapy Program,
Dana-Farber Cancer Institute
Julie Porter
Vice President, Stem Cell Transplant and Cell Therapies,
Dana-Farber Cancer Institute
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AMA PRA Category 1 Credits™
Mass General Brigham designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
Mass General Brigham designates this activity for 3.5 ANCC Nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.
Available Credit
- 3.50 AMA PRA Category 1 Credit™
- 3.50 Nursing Contact Hours
- 3.50 Participation
Price
If you are having difficulty registering for the event, please reach out to the Mass General Brigham Office of Continuing Professional Development at partnerscpd@partners.org
CANCELLATION POLICY:
Registrations cancelled on or before September 9, 2022 will be refunded, less a $15 administrative fee. Registrations cancelled after September 9, 2022 will not be refunded.
Contact partnerscpd@partners.org if you require assistance in cancelling your online registration.